Tyche Industries (532384)

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 1/1

Key Financials

Strengths

• Price-to-book of 1.29, close to book value ₹136.01, limits downside if the book is credible
• ROCE at 12.67% is meaningfully above ROE, suggesting operating assets still generate some return
• Dividend yield of 2.63% offers a modest income cushion
• Small market cap of ₹181 Cr provides room for a genuine turnaround to move the stock

Concerns

• Sales down 40.39% and profit down 61.60% — business is contracting sharply
• Piotroski F-Score of 3/9 points to poor fundamental health
• Trading at ₹175.10, near the 52-week high, while P/E of 17.45 is not cheap on depressed earnings
• ROE of 5.10% is weak for a pharmaceutical company

AI Analysis

Let's look at Tyche Industries without romance. A pharmaceutical company with a ₹181 crore market cap, trading at ₹175.10 — at the very top of its 52-week range. Yet reported sales fell 40.39% and profits fell 61.60%. That combination makes no sense to me unless the market is betting on a sharp recovery. I don't bet on hope. Book value is ₹136.01, so the price-to-book of 1.29 is not extreme. But the return on that book is only 5.10% — barely acceptable. ROCE at 12.67% is better, but with earnings collapsing, that return will likely deteriorate. The Piotroski F-Score of 3/9 is a red flag: this is not a financially improving business. It tells me to look for further deterioration. The latest quarter sales of ₹11 crore and net profit of ₹2 crore, annualised, would support a much lower intrinsic value. At a P/E of 17.45 on depressed earnings, the margin of safety is absent. A 2.63% dividend yield is a small comfort, but dividends are only safe if earnings stabilise. I cannot identify a durable moat from these figures. Pharmaceutical can be good business, but this looks like a small player with no demonstrated pricing power. Graham would say price is what you pay, value is what you get. Here, you are paying for recovery that hasn't shown up in numbers. I would wait for at least two consecutive quarters of sales and profit growth, and for F-Score to improve, before calling this a value opportunity. Right now, it's a possible turnaround, not an established compounder.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer